Clinical trials
Colon Rectal Cancer clinical trials
Below are recruiting colon rectal cancer clinical trials, each written for real people, not researchers. We’re tracking 128 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06028724Recruiting
Looking for cancer mutations using a blood test
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Aviano, PordononeAges 18 years+ - NCT06050447Recruiting
Study on treatment results for colorectal cancer
This study looks at factors that affect outcomes in people with colorectal cancer who have surgery as their main treatment. It aims to help doctors understand how to improve care.
Kaliningrad, Kaliningrad OblastAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06135571Recruiting
Lymph node patterns in left colon and rectal cancer
This study looks at how colon and rectal cancer on the left side spreads to nearby lymph nodes (No.253). It is for people who have had laparoscopic surgery and whose cancer is still only in the colon or rectum. The goal is to better understand these patterns to help guide future treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT06254521RecruitingPhase 2
Tislelizumab plus chemo before surgery for MSS rectal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
Nanning, GuangxiAges 18 years+ - NCT06263088Recruiting
Equity in GI Cancer Care Study
This trial is looking for Black patients newly diagnosed with any stage of gastrointestinal cancer to help improve cancer care and make sure research includes everyone. By joining, you help doctors learn how to better support patients like you.
Cleveland, OhioAges 18 years+ - NCT06340646Recruiting
Washington University cancer gene study
This study collects genetic information from people with certain cancers to learn more about cancer risks and outcomes. It may help researchers understand how genes affect cancer in different groups.
St Louis, MissouriAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Fairfax, VirginiaAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT07406087Recruiting
Navigation support for young adults after cancer
This study tests a navigation program to help cancer survivors ages 21-45 get the follow-up care they need. It may be a good fit if you were diagnosed with certain cancers as a teen or young adult.
Pasadena, CaliforniaAges 21–45 - NCT06746012Recruiting
Health app study for colorectal cancer survivors and their caregivers
This study tests a mobile health program to help colorectal cancer survivors and their family caregivers stick to healthy lifestyle habits. It's for survivors who are at least 6 months past treatment and have a smartphone.
Columbus, OhioAges 18 years+ - NCT06850090RecruitingPhase 3
Comparing two chemo drugs before radiation for rectal cancer
This trial tests if a newer chemo pill (TAS-102) works better than the standard pill (capecitabine) when given before radiation and surgery for rectal cancer. It is for people with stage II or III rectal cancer that has certain high-risk features.
Jinan, ShandongAges 18–75 - NCT06972160Recruiting
Boosting colorectal cancer screening in Barcelos/Esposende
This study looks at ways to help more people get screened for colorectal cancer. If you're between 50 and 74 and haven't had certain screenings recently, you may be able to join.
PortoAges 49–75 - NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT07056374Recruiting
New bowel connection method for colon or rectal cancer surgery
This trial tests a new way of connecting the bowel after removing cancer or precancerous lesions in the sigmoid colon or upper rectum. It is for patients who are having planned, curative surgery and may help reduce complications.
AmsterdamAges 18 years+ - NCT07098182Recruiting
Preserving blood supply during colon or rectal surgery
This trial tests a technique during colon or rectal surgery to preserve a specific blood vessel (the left colic artery) that helps keep the remaining colon healthy. It is for people with left colon, rectal, or ovarian cancer who are scheduled for surgery.
Montpellier, HeraultAges 18 years+ - NCT07179692RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Dublin, CaliforniaAges 18 years+ - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Greenwood Village, ColoradoAges 19–110 - NCT07675967Recruiting
Blood Cell Changes During Cancer Treatment
This study is for people with solid tumors who are about to start chemotherapy or radiation. It looks at how these treatments affect blood cells and may help doctors understand changes in blood health over time.
Boston, MassachusettsAges 18 years+ - NCT07405476RecruitingPhase 2
Zanidatamab before surgery for HER2 positive colon or rectal cancer
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Atlanta, GeorgiaAges 18 years+
Hear when a new Colon Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colon rectal cancer?
- Yes. Clin2 currently lists 128 recruiting colon rectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colon rectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colon rectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.